Related Experiment Video
Updated: Apr 5, 2026
A Mouse Model of Mechanotransduction-driven, Human-like Hypertrophic Scarring
Published on: November 29, 2024
Paclitaxel reduces formation of hypertrophic scars in the rabbit ear model
Li-Ping Huang1, Guo-Qi Wang2, Zi-Shan Jia1
1Department of Physical Therapy, Chinese PLA General Hospital, Beijing, People's Republic of China.
Background And Objective:
The onset and progression of pathological scarring involves multiple cytokines and complex mechanisms. However, hyperplasia of fibroblasts and neovascularization plays important roles, which can be inhibited by paclitaxel. The aim of this study was to investigate the efficacy of paclitaxel in the treatment of hypertrophic scars on rabbit ears.
Methods:
Rabbit ear models of hypertrophic scars were established to observe the therapeutic effects of paclitaxel at different concentrations (12 mg/L, 24 mg/L, 48 mg/L, 96 mg/L, 18 mg/L, 54 mg/L, 162 mg/L, 486 mg/L, 30 mg/L, 150 mg/L, 750 mg/L, 3,750 mg/L). The outcome measures included hypertrophic index (HI), density of fibroblasts, density of collagenous fibers, and microvessel density.
Results:
In comparison with the control group, the concentrations of 96 mg/L, 150 mg/L, and 162 mg/L significantly reduce the formation of hypertrophic scars in the rabbit ear models. However, local necrosis was found in the rabbit ear models treated with paclitaxel solution >400 mg/L.
Conclusion:
Paclitaxel has strong inhibitory effects on the hyperplasia of fibroblasts, deposition of collagen, and microangiogenesis in hypertrophic scars on rabbit ears within the concentration range from 48 mg/L to 162 mg/L, without causing local necrosis.
Insights
Paclitaxel effectively treats hypertrophic scars by inhibiting fibroblast hyperplasia and neovascularization in rabbit ears. Optimal concentrations range from 48-162 mg/L, avoiding necrosis.
Area of Science:
- Dermatology
- Wound Healing
- Pharmacology
Background:
- Pathological scarring involves complex cytokine interactions.
- Fibroblast hyperplasia and neovascularization are key drivers of hypertrophic scars.
- Paclitaxel demonstrates inhibitory potential against these scar-promoting mechanisms.
Purpose of the Study:
- To evaluate the therapeutic efficacy of paclitaxel in treating hypertrophic scars.
- To determine the optimal concentration range of paclitaxel for scar treatment.
- To assess the safety profile of paclitaxel concerning local tissue necrosis.
Main Methods:
- Hypertrophic scar models were established on rabbit ears.
- Paclitaxel was administered at various concentrations (12-3750 mg/L).
- Outcomes measured included hypertrophic index, fibroblast density, collagen fiber density, and microvessel density.
Main Results:
- Concentrations of 96 mg/L, 150 mg/L, and 162 mg/L significantly reduced hypertrophic scar formation.
- Paclitaxel concentrations exceeding 400 mg/L resulted in local necrosis in rabbit ear models.
- Inhibition of fibroblast hyperplasia, collagen deposition, and microangiogenesis was observed.
Conclusions:
- Paclitaxel exhibits significant inhibitory effects on key hypertrophic scar components.
- Effective concentrations for scar treatment range from 48 mg/L to 162 mg/L.
- Paclitaxel is safe for hypertrophic scar treatment within this effective concentration range, without inducing local necrosis.
